Shire Receives EU’s MAA for VEYVONDI for the Treatment of von Willebrand disease in adults

 Shire Receives EU’s MAA for VEYVONDI for the Treatment of von Willebrand disease in adults

Shire Receives EU’s MAA for VEYVONDI for the Treatment of von Willebrand disease in adults

Shots:

  • Approval is based on three clinical trials (N=80) assessing safety, tolerability, PK, haemostatic efficacy of rVWF in adults: P-III for rFVIII with severe VWD; P-III for rFVIII and rVWF in the treatment of bleeding episodes with severe VWD; P-III with severe VWD undergoing major/ minor/oral elective surgical procedures (w/o rFVIII)
  • VEYVONDI [vonicog alfa, recombinant von Willebrand factor] novel rVWF treatment for VWD in EU and for treating haemorrhage and treat surgical bleeding in adults. It can’t be used to treat Haemophilia A
  • VEYVONDI will now be marketed in 28 Member States of the EU (Incl. Iceland, Lichtenstein and Norway) and is available in the US as VONVENDI [von Willebrand factor (Recombinant)] for VWD

Click here to read full press release/ article | Ref: Shire | Image: Investor’s Business Daily

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post